Edwards Lifesciences Corp (NYSE:EW) – Stock analysts at SunTrust Banks increased their Q1 2018 EPS estimates for Edwards Lifesciences in a research report issued on Wednesday. SunTrust Banks analyst B. Nudell now anticipates that the medical research company will post earnings of $1.11 per share for the quarter, up from their prior estimate of $1.10. SunTrust Banks currently has a “Buy” rating and a $150.00 price target on the stock. SunTrust Banks also issued estimates for Edwards Lifesciences’ Q2 2018 earnings at $1.15 EPS, Q3 2018 earnings at $1.04 EPS, Q4 2018 earnings at $1.22 EPS, FY2018 earnings at $4.52 EPS, FY2019 earnings at $5.26 EPS, FY2020 earnings at $5.87 EPS, FY2021 earnings at $6.49 EPS and FY2022 earnings at $7.06 EPS.
Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, February 1st. The medical research company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.91 by $0.03. The business had revenue of $888.50 million for the quarter, compared to the consensus estimate of $868.45 million. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.69%. The firm’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same period last year, the firm posted $0.75 earnings per share.
Edwards Lifesciences (NYSE EW) opened at $123.78 on Friday. The firm has a market cap of $27,447.10, a P/E ratio of 42.98, a PEG ratio of 1.92 and a beta of 0.63. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.15. Edwards Lifesciences has a 1 year low of $89.20 and a 1 year high of $138.48.
Edwards Lifesciences declared that its board has approved a stock buyback plan on Thursday, December 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board of directors believes its shares are undervalued.
In other news, VP Robert W.A. Sellers sold 12,020 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $131.03, for a total value of $1,574,980.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $127.24, for a total transaction of $674,372.00. Following the completion of the sale, the vice president now owns 24,908 shares of the company’s stock, valued at $3,169,293.92. The disclosure for this sale can be found here. Insiders sold 175,940 shares of company stock valued at $20,049,578 over the last quarter. Corporate insiders own 2.13% of the company’s stock.
Several institutional investors have recently modified their holdings of EW. Koch Industries Inc. raised its stake in Edwards Lifesciences by 28,363.1% during the 2nd quarter. Koch Industries Inc. now owns 1,397,254 shares of the medical research company’s stock valued at $1,386,000 after purchasing an additional 1,392,345 shares during the last quarter. Atlantic Trust Group LLC raised its stake in Edwards Lifesciences by 734.7% during the 3rd quarter. Atlantic Trust Group LLC now owns 914,989 shares of the medical research company’s stock valued at $100,018,000 after purchasing an additional 805,370 shares during the last quarter. Janus Henderson Group PLC raised its stake in Edwards Lifesciences by 1,135.0% during the 3rd quarter. Janus Henderson Group PLC now owns 619,703 shares of the medical research company’s stock valued at $67,739,000 after purchasing an additional 569,525 shares during the last quarter. Old Mutual Global Investors UK Ltd. raised its stake in Edwards Lifesciences by 83.0% during the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 1,100,885 shares of the medical research company’s stock valued at $120,337,000 after purchasing an additional 499,436 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in Edwards Lifesciences by 20.2% during the 3rd quarter. Wells Fargo & Company MN now owns 2,548,282 shares of the medical research company’s stock valued at $278,553,000 after purchasing an additional 429,022 shares during the last quarter. Institutional investors and hedge funds own 81.52% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.com-unik.info/2018/02/09/brokers-offer-predictions-for-edwards-lifesciences-corps-q1-2018-earnings-ew.html.
About Edwards Lifesciences
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.